💊Astellas Acquires Universal Cells, Inc.
Tokyo, February 13, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO:
Yoshihiko Hatanaka, “Astellas”) and Universal Cells, Inc. (CEO: Claudia Mitchell,
“Universal Cells”) today announced that Astellas has acquired Universal Cells. Astellas
will gain Universal Cells’ proprietary Universal Donor Cell technology to create cell
therapy products that do not require Human Leukocyte Antigen (HLA) matching,
potentially overcoming a huge treatment challenge by reducing the risk of rejection. .
Astellas : News Releases /
https://www.astellas.com/en/corporate/news/pdf/180214_1_Eg.pdf